eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank

 
5/2020
vol. 16
 
Share:
Share:
more
 
 
Lipid disorders
abstract:
Clinical research

Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia)

Vincent A. Pallazola
1
,
Vasanth Sathiyakumar
1
,
Jihwan Park
2
,
Rachit M. Vakil
1
,
Peter P. Toth
1, 3
,
Mariana Lazo-Elizondo
2, 4
,
Emily Brown
1
,
Renato Quispe
1, 4
,
Eliseo Guallar
2, 4
,
Maciej Banach
5
,
Roger S. Blumenthal
1
,
Steven R. Jones
1
,
David Marais
6
,
Daniel Soffer
7
,
Allan D. Sniderman
8
,
Seth S. Martin
1, 4

1.
Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
3.
Department of Medicine, Community Hospital General Medical Center, Sterling, IL, USA
4.
Welch Center for Prevention, Epidemiology, and Clinical Research, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
5.
Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland
6.
Department of Internal Medicine, University of Cape Town Health Sciences, Cape Town, South Africa
7.
Department of Medicine and Institute for Translational Medicine and Therapeutics, University of Pennsylvania Health System, Philadelphia, PA
8.
Division of Cardiology, McGill University Health Centre, Montreal, Quebec, Canada
Arch Med Sci 2020; 16 (5): 993–1003
Online publish date: 2019/08/02
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Dysbetalipoproteinaemia (HLP3) is a disorder characterized by excess cholesterol-enriched, triglyceride-rich lipoprotein remnants in genetically predisposed individuals that powerfully promote premature cardiovascular disease if untreated. The current prevalence of HLP3 is largely unknown.

Material and methods
We performed cross-sectional analysis of 128,485 U.S. adults from the Very Large Database of Lipids (VLDbL), using four algorithms to diagnose HLP3 employing three Vertical Auto Profile ultracentrifugation (UC) criteria and a previously described apolipoprotein B (apoB) method. We evaluated 4,926 participants from the 2011–2014 National Health and Nutrition Examination Survey (NHANES) with the apoB method. We examined demographic and lipid characteristics stratified by presence of HLP3 and evaluated lipid characteristics in those with HLP3 phenotype discordance and concordance as determined by apoB and originally defined UC criteria 1.

Results
In U.S. adults in VLDbL and NHANES, a 1.7–2.0% prevalence is observed for HLP3 with the novel apoB method as compared to 0.2–0.8% prevalence in VLDbL via UC criteria 1–3. Participants who were both apoB and UC criteria HLP3 positive had higher remnant particles as well as more elevated triglyceride/apoB and total cholesterol/apoB ratios (all p < 0.001) than those who were apoB method positive and UC criteria 1 negative.

Conclusions
HLP3 may be more prevalent than historically and clinically appreciated. The apoB method increases HLP3 identification via inclusion of milder phenotypes. Further work should evaluate the clinical implications of HLP3 diagnosis at various lipid algorithm cut-points to evaluate the ideal standard in the modern era.

keywords:

Very Large Database of Lipids (VLDL), National Health and Nutrition Examination Survey, type III hyperlipoproteinemia, dysbetalipoproteinemia, apolipoprotein B

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe